摘要事件:公司发布2025年中期业绩,报告期内公司实现营业收入4.99亿元,实现归母净利润-0.79亿元。IL-4R单抗司普奇拜单抗商业化顺利推进,后续医保谈判值得期待。公司核心产品IL-4R单抗司普奇拜单抗商业化顺利推进中,2025年上半年实现销售额1.7亿元;该产品已获批中重度特应性皮炎、慢性鼻窦炎伴鼻息肉、季节性过敏性鼻炎三大适应症,且已通过2025年医保药品目录调整形式审查,后续医保谈判...
Source Link摘要事件:公司发布2025年中期业绩,报告期内公司实现营业收入4.99亿元,实现归母净利润-0.79亿元。IL-4R单抗司普奇拜单抗商业化顺利推进,后续医保谈判值得期待。公司核心产品IL-4R单抗司普奇拜单抗商业化顺利推进中,2025年上半年实现销售额1.7亿元;该产品已获批中重度特应性皮炎、慢性鼻窦炎伴鼻息肉、季节性过敏性鼻炎三大适应症,且已通过2025年医保药品目录调整形式审查,后续医保谈判...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.